Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models.
Jennifer Swainson, Elisa Brietzke, Atul Khullar, Roger S McIntyre, Claudio N. Soares
The Canadian Journal of Psychiatry October 28, 2025 DOI: 10.1177/07067437251389090 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Perspective Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy Esketamine Ketamine |
| Keywords | Ketamine-assisted psychotherapy Psychedelic psychotherapy Psychedelic medicine Psychedelic integration Psychedelic treatments Psychedelic mental health Psychedelic-enhanced therapy Mental health treatment Mental healthcare Psychiatric care Psychological treatment Mental wellness Behavioral health Mental health services Conceptual models Treatment models Theoretical frameworks Therapeutic frameworks Terminology Nomenclature Reframing Redefinition New language Conceptualization Innovative therapies Novel treatments Cutting-edge therapies Emerging treatments Advanced therapies Therapeutic innovation Synergistic benefits |
| Citations | 2 |
| Key points | Proposes three definitions to distinguish therapeutic models of psychedelic and ketamine treatments: stand-alone pharmacotherapy, drug-assisted psychotherapy, and drug combined with a manualized psychotherapy. |
Abstract
There has been a renewed interest in the use of various psychedelic agents as potential therapies for multiple psychiatric conditions, including post-traumatic stress disorder (PTSD), major depressive disorder (MDD), generalized anxiety disorder (GAD), to name a few. This follows the recent accumulation of evidence for ketamine pharmacotherapy and a rapid proliferation of clinics/programs offering a variety of ketamine based treatments. A quick glance at the existing evidence, however, reveals a confusing scenario for patients, healthcare providers, and regulators. Overall, there are no standard definitions of what constitutes a psychotherapeutic intervention within a psychedelic-based or a ketamine-based treatment. More specifically, studies have not always distinguished between using a well-known, manualized psychotherapy, providing psychoeducation and psychological support, or providing a therapy specifically to integrate the drug experience in psychedelic trials. Also, it is difficult to determine the role of the psychedelic agent as a stand-alone treatment, and the relative importance (if any) of the psychedelic experience for the desired therapeutic effect. In this perspective, we discuss the evolving landscape of psychedelic-based and ketamine-based treatments, highlighting different therapeutic models, their methodologies, and the need for clearer definitions and rigorous clinical trials. The document proposes three new definitions to improve clarity in evaluating the effects of these agents and the role of psychotherapies. We suggest language that will distinguish: (1) when the drug is used for its pharmacologic effects as a stand-alone treatment, without requiring the psychedelic experience or combined psychotherapy; (2) when the treatment requires the acute psychological effects of the drug to assist psychotherapy and (3) When ketamine or a psychedelic agent is used in combination with a structured, manualized psychotherapy that could be implemented even in the absence of these agents. We hope that this new terminology and definitions will help distinguish the various therapeutic roles of these agents (as stand-alone treatments or in combination with psychotherapies), and facilitate study designs, regulatory pathways, and more informed patient care.Plain Language Summary TitleKetamine, Psychedelics, and Psychotherapy: Understanding treatment models to better inform practice.
Citations in the library
Cited by 4
- Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions International Journal of Eating Disorders July 2, 2026
- Combined Ketamine and Cognitive-Behavioral Therapy: Leveraging Metaplasticity to Enhance Treatment Outcomes FOCUS: The Journal of Lifelong Learning in Psychiatry July 1, 2026
- Patient-centred education for ketamine and esketamine therapies in mood disorders. Therapeutic Advances in Psychopharmacology 2026
- Augmentation strategies for intravenous ketamine in treatment-resistant depression: A systematic review and meta-analysis. Journal of Affective Disorders October 12, 2026
Cites 13
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. American Journal of Psychiatry March 29, 2019
- Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy Journal of Psychoactive Drugs March 15, 2019
- The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame) August 13, 2020
- Toward Synergies of Ketamine and Psychotherapy Frontiers in Psychology March 25, 2022
and 8 more in the library